Limits...
Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Hong SP, Park JY, Jeon TJ, Bang S, Park SW, Chung JB, Park MS, Seong J, Lee WJ, Song SY - Br. J. Cancer (2008)

Bottom Line: Overall survival was significantly longer in the low baseline CA19-9 group and therapeutic responders.Toxicities were tolerable and successfully managed by conservative treatments.The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
The aim of this study was to evaluate the efficacy and the toxicity of a full dose of gemcitabine and a single dose of cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Forty-one patients with locally advanced pancreatic cancer were enrolled. Patients received gemcitabine (1000 mg m(-2) on days 1, 8, 15, 29, and 36) and cisplatin (70 mg m(-2) on days 1 and 29) with concurrent radiotherapy (45 Gy in 25 fractions). Treatment was completed in 38 out of 41 patients (92.7%). The overall response rate was 24.4% (two complete and eight partial). Six patients (14.6%) underwent definite pancreatic resection and four had negative surgical margins. The intention of the treatment analysis showed that the median survival time and median time to tumour progression were 16.7 and 8.9 months. The 1- and 2-year survival rates were 63.3 and 27.9%, respectively. Overall survival was significantly longer in the low baseline CA19-9 group and therapeutic responders. Toxicities were tolerable and successfully managed by conservative treatments. The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.

Show MeSH

Related in: MedlinePlus

Cumulative survival of patients based on baseline CA19-9 level (A) and objective response (B). The median survival time of patients with baseline CA19-9 level less than 1000 U ml−1 and more than 1000 U ml−1 were 20.1 and 8.2 months, respectively. The median survival time of patients with objective response (CR+PR), SD, and PD were 18.3, 16.7, and 7.5 months, respectively.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2266862&req=5

fig2: Cumulative survival of patients based on baseline CA19-9 level (A) and objective response (B). The median survival time of patients with baseline CA19-9 level less than 1000 U ml−1 and more than 1000 U ml−1 were 20.1 and 8.2 months, respectively. The median survival time of patients with objective response (CR+PR), SD, and PD were 18.3, 16.7, and 7.5 months, respectively.

Mentions: The prognostic factors influencing the patients' cumulative survival were analysed (Table 2). Univariate analysis revealed four significant predictors of survival: performance status (P=0.002), baseline weight loss (P=0.022), baseline serum CA19-9 levels (P=0.004), and objective therapeutic response (P=0.019) (Figure 2).


Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Hong SP, Park JY, Jeon TJ, Bang S, Park SW, Chung JB, Park MS, Seong J, Lee WJ, Song SY - Br. J. Cancer (2008)

Cumulative survival of patients based on baseline CA19-9 level (A) and objective response (B). The median survival time of patients with baseline CA19-9 level less than 1000 U ml−1 and more than 1000 U ml−1 were 20.1 and 8.2 months, respectively. The median survival time of patients with objective response (CR+PR), SD, and PD were 18.3, 16.7, and 7.5 months, respectively.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2266862&req=5

fig2: Cumulative survival of patients based on baseline CA19-9 level (A) and objective response (B). The median survival time of patients with baseline CA19-9 level less than 1000 U ml−1 and more than 1000 U ml−1 were 20.1 and 8.2 months, respectively. The median survival time of patients with objective response (CR+PR), SD, and PD were 18.3, 16.7, and 7.5 months, respectively.
Mentions: The prognostic factors influencing the patients' cumulative survival were analysed (Table 2). Univariate analysis revealed four significant predictors of survival: performance status (P=0.002), baseline weight loss (P=0.022), baseline serum CA19-9 levels (P=0.004), and objective therapeutic response (P=0.019) (Figure 2).

Bottom Line: Overall survival was significantly longer in the low baseline CA19-9 group and therapeutic responders.Toxicities were tolerable and successfully managed by conservative treatments.The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
The aim of this study was to evaluate the efficacy and the toxicity of a full dose of gemcitabine and a single dose of cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Forty-one patients with locally advanced pancreatic cancer were enrolled. Patients received gemcitabine (1000 mg m(-2) on days 1, 8, 15, 29, and 36) and cisplatin (70 mg m(-2) on days 1 and 29) with concurrent radiotherapy (45 Gy in 25 fractions). Treatment was completed in 38 out of 41 patients (92.7%). The overall response rate was 24.4% (two complete and eight partial). Six patients (14.6%) underwent definite pancreatic resection and four had negative surgical margins. The intention of the treatment analysis showed that the median survival time and median time to tumour progression were 16.7 and 8.9 months. The 1- and 2-year survival rates were 63.3 and 27.9%, respectively. Overall survival was significantly longer in the low baseline CA19-9 group and therapeutic responders. Toxicities were tolerable and successfully managed by conservative treatments. The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.

Show MeSH
Related in: MedlinePlus